Madhav Vissa

Pediatric Hematologist-Oncologist

Assessment of total and unbound cell-free heme in plasma of patients with sickle cell disease.

Experimental biology and medicine (Maywood, N.J.)

Vissa M, Larkin SK, Vichinsky EP, Kuypers FA, Soupene E

Voxelotor for the treatment of sickle cell disease.

Expert review of hematology

Vissa M, Vichinsky E

A pragmatic multi-institutional approach to understanding transplant-associated thrombotic microangiopathy after stem cell transplant.

Blood advances

Dandoy CE, Rotz S, Alonso PB, Klunk A, Desmond C, Huber J, Ingraham H, Higham C, Dvorak CC, Duncan C, Schoettler M, Lehmann L, Cancio M, Killinger J, Davila B, Phelan R, Mahadeo KM, Khazal S, Lalefar N, Vissa M, Myers K, Wallace G, Nelson A, Khandelwal P, Bhatla D, Gloude N, Anderson E, Huo J, Roehrs P, Auletta JJ, Chima R, Lane A, Davies SM, Jodele S

Risk Factors for Transplant-Associated Thrombotic Microangiopathy after Autologous Hematopoietic Cell Transplant in High-Risk Neuroblastoma.

Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation

Tolbert VP, Dvorak CC, Golden C, Vissa M, El-Haj N, Perwad F, Matthay KK, Vo KT

Unexpected Anemia and Reticulocytopenia in an Adolescent With Sickle Cell Anemia Receiving Chronic Transfusion Therapy.

Journal of pediatric hematology/oncology

Blauel ER, Grossmann LT, Vissa M, Miller ST